OMGA Company Profile and Key Details

Q: Who are the executives of OMGA?

Ms. Barbara Y. ChanSenior Vice President of Fin.Mr. Joshua Reed M.B.A.Chief Financial OfficerDr. Thomas McCauleyChief Scientific OfficerMs. Ling Zeng Esq., J.D.Chief Legal & Admin. Officer and Sec.Mr. Kevin McManusChief HR OfficerDr. Sivakesava Sakhamuri Ph.D.Senior Vice President and Head of Technical Operations & QualityMr. Mahesh KarandePres, Chief Executive Officer & Board DirectorMr. Charles O'Donnell Ph.D.Vice President and Head of Computational Genomics & Data SciencesDr. Noubar B. Afeyan Ph.D.Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board

NASDAQ : OMGA

Omega Therapeutics

$0.14

At Close 4:00 PM

Not Actively Trading

59.99

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Omega Therapeutics, Inc. (OMGA) stock remained unchanged at $0.14 a share on NASDAQ. The stock opened at $0.17, fluctuating between $0.14 to $0.17 during the session.

Stock Snapshot

0.1426

Prev. Close

7.9M

Market Cap

0.1426

Day Low

-0.10803030303030303

P/E Ratio

-1.32

EPS (TTM)

-1.71

Cash Flow per Share

0.17

Open

55.37M

Number of Shares

0.166

Day High

39.26%

Free Float in %

1.05

Book Value

4.28M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 24, 2025	0.01	0.02	0.01	0.02	261.86K
Mar 21, 2025	0.01	0.02	0.01	0.01	321.91K
Mar 19, 2025	0.01	0.01	0.01	0.01	77.51K
Mar 17, 2025	0.02	0.02	0.01	0.01	112.97K
Mar 14, 2025	0.02	0.02	0.01	0.02	345.15K
Mar 11, 2025	0.01	0.01	0.01	0.01	75.53K
Mar 07, 2025	0.01	0.02	0.01	0.01	282.89K
Mar 06, 2025	0.01	0.02	0.01	0.01	200.62K
Mar 04, 2025	0.02	0.02	0.01	0.01	293.83K
Mar 03, 2025	0.02	0.03	0.02	0.02	875.09K
Feb 28, 2025	0.03	0.04	0.03	0.03	562.65K
Feb 27, 2025	0.06	0.07	0.03	0.03	991.14K
Feb 26, 2025	0.14	0.14	0.06	0.07	1.69M
Feb 24, 2025	0.17	0.17	0.14	0.14	5.15M
Feb 21, 2025	0.17	0.22	0.16	0.16	21.38M
Feb 20, 2025	0.18	0.19	0.15	0.15	3.33M
Feb 19, 2025	0.21	0.22	0.18	0.19	3.91M
Feb 18, 2025	0.21	0.25	0.20	0.21	5.83M
Feb 14, 2025	0.21	0.25	0.15	0.23	10.47M
Feb 13, 2025	0.21	0.25	0.20	0.22	13.33M

Contact Details

Cambridge, MA 02140

United States

https://www.omegatherapeutics.com 617 949 4360

About Company

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

-23.33-2.78%

argenx SE$816.95 REGN

12.09+1.57%

Regeneron Pharmaceuticals, Inc.$784.28 UTHR

61.67+13.03%

United Therapeutics Corporation$535.10 VRTX

-4.38-0.90%

Vertex Pharmaceuticals Incorporated$483.05 MDGL

-4.99-1.13%

Madrigal Pharmaceuticals, Inc.$435.01 PRAX

4.84+1.41%

Praxis Precision Medicines, Inc.$347.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.49-1.65%

Alnylam Pharmaceuticals, Inc.$327.36 KRYS

5.6+2.10%

Krystal Biotech, Inc.$272.50 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

The stock is currently mid-range between its 52-week high and low $0.03 and $4.44. With a market capitalization of about $7.90 million, Omega Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.64). Key stats such as the average daily volume over the past year has been around 9.59 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Omega Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kaan Certel, the company employs approximately 93 people and listed since July 30, 2021. Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company.

Technical Performance

OMGA has shown weak momentum, losing -81.17% over the past week and -96.31% over the past quarter, though year-to-date performance is down -96.11%. Short-term trend indicators are bullishly aligned (SMA20 -45.71%, SMA50 -74.49%, SMA200 -89.06%). The stock’s 14-day RSI is 30.39 (weak momentum), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.8% below its high and over 49.63% above its low.

Valuation Metrics

Omega Therapeutics, Inc. trades at a P/E ratio of -0.08, slightly below the S&P 500 average, with a price-to-sales ratio of 2.55 and a price-to-book ratio of 0.13 suggesting the stock is closer to book value. The P/FCF stands at -0.08, also above market averages.

Dividend & Fair Value

Omega Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$3.25. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.28. Next year's EPS is expected at $8.12. Omega Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 27, 2025, missed forecasts by 32.14%. The prior quarter beat by 3.45%. Over the last six quarters, Apple has recorded several small beats. These include -2.63% in May 02, 2024.

Shareholding & Insider Activity

Omega Therapeutics, Inc. has 55.37 million shares outstanding. The public float is 21.73 million shares, elevated short interest at 26.91% of float. This equals 5.21 million shares. The short ratio is 6.97 days. Institutional investors hold 89.24% of the float. Insiders own 1.67%. Invus Public Equities, L.P. holds 2.27 million shares, Flagship Pioneering Inc. has 1.33 million shares and Young Richard A has 739.12 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Omega Therapeutics generated $3.09M in revenue, or $0.06 per share. Gross margin was -118.84%, operating margin -3240.50%, and net profit margin -3148.93%. Returns are negative, with ROA at -47.67% and ROE at -167.93%.
On valuation metrics, Omega Therapeutics trades at a P/E of -0.08, P/S of 2.55 and P/B of 0.13. The current ratio is 3.35 and quick ratio is 3.34. Operationally, the company’s inventory turnover is 217.39 and cash conversion cycle is 816.84 days. Debt-to-equity is 2.21, supported by a cash flow-to-debt ratio of -0.71.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Omega Therapeutics posted revenue of $3.09M, down slightly from $2.07M in the prior quarter. Gross profit was - $3.68M (margin -118.84%). Operating income was - $100.26M (margin -3240.5%). Net income was- $97.43M (EPS - $1.80).
The company ended the quarter with $73.43M in cash and short-term investments, a total debt of $128.43M, and net debt of $59.99M. Total assets were $204.37M, with equity of $58.02M. Financials further reflected weakness, with operating cash flow of - $91.51M, free cash flow of - $94.38M, and capital expenditures of - $2.87M.

Price Forecast & Outlook

Our AI price prediction model suggests that Omega Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by April 07, 2025, within a range of $0.00 to $0.00 3-Month Outlook: Projected fall of -41.18%, reaching $0.01 by May 29, 2025, with a range of $0.00 to $0.11. 1-Year Outlook: Projected gain of 252.94%, with price at $0.06 by February 27, 2026, within a range of $0.00 to $0.00.

Key Takeaways

Omega Therapeutics, Inc. (NASDAQ:OMGA) shares are down -96.11% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Omega Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.08. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $11.00, suggesting 64605.88% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-41.18% over three months), and a longer-term gain (252.94% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Omega Therapeutics, Inc. (OMGA) stock price?

Omega Therapeutics, Inc. (NASDAQ: OMGA) stock price is $0.14 in the last trading session. During the trading session, OMGA stock reached the peak price of $0.17 while $0.14 was the lowest point it dropped to. The percentage change in OMGA stock occurred in the recent session was 0% while the dollar amount for the price change in OMGA stock was $0.00.

OMGA's industry and sector of operation?

The NASDAQ listed OMGA is part of Biotechnology industry that operates in the broader Healthcare sector. Omega Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OMGA?

Ms. Barbara Y. Chan
Senior Vice President of Fin.
Mr. Joshua Reed M.B.A.
Chief Financial Officer
Dr. Thomas McCauley
Chief Scientific Officer
Ms. Ling Zeng Esq., J.D.
Chief Legal & Admin. Officer and Sec.
Mr. Kevin McManus
Chief HR Officer
Dr. Sivakesava Sakhamuri Ph.D.
Senior Vice President and Head of Technical Operations & Quality
Mr. Mahesh Karande
Pres, Chief Executive Officer & Board Director
Mr. Charles O'Donnell Ph.D.
Vice President and Head of Computational Genomics & Data Sciences
Dr. Noubar B. Afeyan Ph.D.
Co-Founder, Independent Non Executive Chairman & Member of Technology Advisory Board

How OMGA did perform over past 52-week?

OMGA's closing price is 468.13% higher than its 52-week low of $0.03 where as its distance from 52-week high of $4.44 is -96.79%.

How many employees does OMGA have?

Number of OMGA employees currently stands at 93.

Link for OMGA official website?

Official Website of OMGA is: https://www.omegatherapeutics.com

How do I contact OMGA?

OMGA could be contacted at phone 617 949 4360 and can also be accessed through its website. OMGA operates from 20 Acorn Park Drive, Cambridge, MA 02140, United States.

How many shares of OMGA are traded daily?

OMGA stock volume for the day was 4.28M shares. The average number of OMGA shares traded daily for last 3 months was 9.59M.

What is the market cap of OMGA currently?

The market value of OMGA currently stands at $7.90M with its latest stock price at $0.14 and 55.37M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	93
Beta	1.64
Sales or Revenue	$3.09M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

OMGA Company Profile and Key Details

Omega Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Earnings & Analyst Outlook

Technical Performance

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics